Researchmoz added Most up-to-date research on "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2018" to its huge collection of research reports.
This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.
FREE| Request Sample is Available at: https://www.researchmoz.us/enquiry.php?type=S&repid=1497548
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman's external genitals, called the vulva.
The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.
Scope
Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?
Get complete TOC with Tables and Figures at: https://www.researchmoz.us/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-report.html/toc
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
List of Table
Table 1: Number of Products under Development for Cervical Cancer 9
Table 2: Number of Products under Development by Companies, Cervical Cancer 11
Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 15
Table 4: Products under Development by Companies, Cervical Cancer 16
Table 5: Products under Development by Universities/Institutes, Cervical Cancer 22
Table 6: Number of Products under Development for Vaginal Cancer 24
Table 7: Number of Products under Development by Companies, Vaginal Cancer 25
Table 8: Products under Development by Companies, Vaginal Cancer 26
Table 9: Number of Products under Development for Vulvar Cancer 27
Table 10: Number of Products under Development by Companies, Vulvar Cancer 28
Table 11: Products under Development by Companies, Vulvar Cancer 29
Table 12: Number of Products by Stage and Target, Cervical Cancer 31
Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer 35
...
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1497548
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us ;
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com
This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.
FREE| Request Sample is Available at: https://www.researchmoz.us/enquiry.php?type=S&repid=1497548
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman's external genitals, called the vulva.
The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.
Scope
Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?
Get complete TOC with Tables and Figures at: https://www.researchmoz.us/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-report.html/toc
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
List of Table
Table 1: Number of Products under Development for Cervical Cancer 9
Table 2: Number of Products under Development by Companies, Cervical Cancer 11
Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 15
Table 4: Products under Development by Companies, Cervical Cancer 16
Table 5: Products under Development by Universities/Institutes, Cervical Cancer 22
Table 6: Number of Products under Development for Vaginal Cancer 24
Table 7: Number of Products under Development by Companies, Vaginal Cancer 25
Table 8: Products under Development by Companies, Vaginal Cancer 26
Table 9: Number of Products under Development for Vulvar Cancer 27
Table 10: Number of Products under Development by Companies, Vulvar Cancer 28
Table 11: Products under Development by Companies, Vulvar Cancer 29
Table 12: Number of Products by Stage and Target, Cervical Cancer 31
Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer 35
...
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1497548
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us ;
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com
No comments:
Post a Comment